MCID: PLY041
MIFTS: 58

Polymyositis

Categories: Bone diseases, Immune diseases, Muscle diseases, Nephrological diseases, Neuronal diseases, Rare diseases, Respiratory diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Polymyositis

MalaCards integrated aliases for Polymyositis:

Name: Polymyositis 11 19 52 58 75 53 14 16 71 31 33
Pm - [polymyositis] 33

Characteristics:


Prevelance:

1-9/1000000 (Europe, Argentina, Australia, Spain, Sweden) 1-9/100000 (Europe, Argentina, Australia) 58

Age Of Onset:

Adult,Elderly 58

Age Of Death:

adult 58

Classifications:

Orphanet: 58  
Rare neurological diseases
Rare renal diseases
Rare systemic and rhumatological diseases


Summaries for Polymyositis

NINDS: 52 Polymyositis is one of a group of muscle diseases known as the inflammatory myopathies, which are characterized by chronic muscle inflammation accompanied by muscle weakness.  Polymyositis affects skeletal muscles (those involved with making movement) on both sides of the body.  It is rarely seen in persons under age 18; most cases are in adults between the ages of 31 and 60.  Progressive muscle weakness starts in the proximal muscles (muscles closest to the trunk of the body) which eventually leads to difficulties climbing stairs, rising from a seated position, lifting objects, or reaching overhead.  People with polymyositis may also experience arthritis, shortness of breath, difficulty swallowing and speaking, and heart arrhythmias.  In some cases of polymyositis, distal muscles (muscles further away from the trunk of the body, such as those in the forearms and around the ankles and wrists) may be affected as the disease progresses.  Polymyositis may be associated with collagen-vascular or autoimmune diseases, such as lupus.  Polymyositis may also be associated with infectious disorders, such as HIV-AIDS.

MalaCards based summary: Polymyositis, also known as pm - [polymyositis], is related to inclusion body myositis and interstitial lung disease. An important gene associated with Polymyositis is RN7SL1 (RNA Component Of Signal Recognition Particle 7SL1), and among its related pathways/superpathways are miRNAs involved in DNA damage response and miRNAs involvement in the immune response in sepsis. The drugs Prednisone and Prednisolone phosphate have been mentioned in the context of this disorder. Affiliated tissues include skeletal muscle, heart and bone, and related phenotypes are autoimmunity and emg abnormality

GARD: 19 Polymyositis is a type of inflammatory myopathy, which refers to a group of muscle diseases characterized by chronic muscle inflammation and weakness. The muscles affected by Polymyositis are the skeletal muscles (those involved with making movements) on both sides of the body. The disease is more common among women and among black individuals. The exact cause of Polymyositis is unknown. The disease shares many characteristics with autoimmune disorders, which occur when the immune system mistakenly attacks healthy body tissues. In some cases, the disease may be associated with viral infections, connective tissue disorders, or an increased risk for malignancies (cancer). Diagnosis is based on a clinical examination that may include laboratory tests, imaging studies, electromyography, and a muscle biopsy.

Orphanet: 58 A rare idiopathic inflammatory myopathy (IIM) historically characterized by symmetric proximal muscle weakness, elevated muscle enzymes (creatine kinase), myopathic findings on electromyography, and muscle biopsy showing endomyial infiltration composed mainly of macrophages and lymphocytes. The features are non-specific, thus the disease should be distinguished from similar entities with specific clinical, immunological, histological features, notably dermatomyositis, immune-mediated necrotizing myopathy, anti-synthetase syndrome, inclusion body myositis, and myositis associated with other connective tissue disorder.

Disease Ontology: 11 A myositis that is characterized by muscle weakness affecting both sides of your body.

Wikipedia: 75 Polymyositis (PM) is a type of chronic inflammation of the muscles (inflammatory myopathy) related to... more...

Related Diseases for Polymyositis

Diseases in the Polymyositis family:

Juvenile Polymyositis

Diseases related to Polymyositis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 858)
# Related Disease Score Top Affiliating Genes
1 inclusion body myositis 31.2 MIR34A MIR222 MIR221 MIR214 MIR21 MIR155
2 interstitial lung disease 31.2 MIR30A MIR214 MIR21 MIR155
3 peripheral t-cell lymphoma 29.8 MIR34A MIR21 MIR155
4 nasopharyngeal carcinoma 29.7 MIR30A MIR214 MIR21 MIR155 MIR132 MIR130A
5 thyroid cancer, nonmedullary, 1 29.6 MIR222 MIR221 MIR146B
6 follicular adenoma 29.6 MIR222 MIR221 MIR146B
7 papillary adenocarcinoma 29.5 MIR30A MIR221 MIR21
8 retinal vascular disease 29.4 MIR30A MIR210 MIR21 MIR146B
9 skin disease 29.4 MIR34A MIR30A MIR221 MIR21 MIR155
10 immune deficiency disease 29.3 MIR34A MIR30A MIR221 MIR210 MIR21 MIR155
11 peripheral nervous system disease 29.2 MIR362 MIR34A MIR30A MIR21 MIR132 MIR127
12 leukemia, acute lymphoblastic 29.2 MIR222 MIR221 MIR214 MIR210 MIR21 MIR199B
13 cerebrovascular disease 29.2 MIR30A MIR221 MIR210 MIR21 MIR155 MIR132
14 diffuse large b-cell lymphoma 29.1 MIR222 MIR221 MIR214 MIR210 MIR21 MIR155
15 melanoma 29.1 MIR34A MIR222 MIR221 MIR210 MIR21 MIR199B
16 kidney cancer 29.1 MIR30A MIR221 MIR214 MIR210 MIR21
17 myocardial infarction 28.8 MIR34A MIR30A MIR210 MIR21 MIR155 MIR132
18 leukemia, chronic lymphocytic 28.8 MIR34A MIR30A MIR221 MIR214 MIR21 MIR155
19 aortic valve disease 2 28.7 MIR382 MIR379 MIR34A MIR21 MIR132
20 esophageal cancer 28.7 MIR34A MIR30A MIR222 MIR221 MIR214 MIR21
21 ovarian cancer 28.7 MIR34A MIR30A MIR222 MIR221 MIR214 MIR210
22 ovarian disease 28.6 MIR34A MIR30A MIR222 MIR221 MIR214 MIR21
23 bone disease 28.5 MIR34A MIR30A MIR222 MIR221 MIR214 MIR210
24 hematologic cancer 28.5 MIR34A MIR30A MIR222 MIR221 MIR214 MIR210
25 cervical cancer 28.5 MIR34A MIR30A MIR221 MIR214 MIR210 MIR21
26 miyoshi muscular dystrophy 1 28.4 MIR222 MIR221 MIR214 MIR210 MIR21 MIR155
27 lymphatic system disease 28.3 MIR34A MIR30A MIR222 MIR221 MIR214 MIR210
28 lymphoma, non-hodgkin, familial 28.3 MIR382 MIR34A MIR30A MIR222 MIR214 MIR21
29 lipoprotein quantitative trait locus 28.3 MIR34A MIR30A MIR222 MIR221 MIR214 MIR210
30 alzheimer disease, familial, 1 28.2 MIR501 MIR34A MIR30A MIR210 MIR21 MIR132
31 leukemia, acute myeloid 28.2 MIR362 MIR34A MIR30A MIR222 MIR221 MIR210
32 eye disease 28.2 MIR34A MIR30A MIR221 MIR214 MIR210 MIR21
33 intestinal disease 28.2 MIR34A MIR30A MIR222 MIR221 MIR214 MIR210
34 prostate cancer 28.1 MIR99B MIR34A MIR30A MIR222 MIR221 MIR214
35 gastrointestinal system disease 28.0 MIR34A MIR30A MIR222 MIR221 MIR214 MIR210
36 pancreatic ductal adenocarcinoma 27.9 MIR501 MIR34A MIR30A MIR222 MIR221 MIR214
37 pancreatic cancer 27.8 MIR501 MIR34A MIR30A MIR222 MIR221 MIR214
38 dermatomyositis 27.8 RN7SL1 MIR99B MIR501 MIR382 MIR379 MIR362
39 connective tissue disease 27.6 MIR501 MIR382 MIR362 MIR34A MIR30A MIR222
40 muscular dystrophy, duchenne type 27.5 MIR382 MIR379 MIR34A MIR30A MIR222 MIR221
41 facioscapulohumeral muscular dystrophy 1 27.5 MIR99B MIR379 MIR34A MIR222 MIR221 MIR214
42 renal cell carcinoma, nonpapillary 27.0 MIR99B MIR501 MIR362 MIR34A MIR30A MIR222
43 lung cancer 26.9 MIR382 MIR362 MIR34A MIR30A MIR222 MIR221
44 nemaline myopathy 26.5 MIR382 MIR379 MIR362 MIR34A MIR30A MIR222
45 myositis 11.5
46 juvenile polymyositis 11.4
47 mixed connective tissue disease 11.3
48 myopathy 11.2
49 childhood type dermatomyositis 11.2
50 systemic scleroderma 11.1

Comorbidity relations with Polymyositis via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Dermatomyositis Heart Disease
Hypertension, Essential Hypothyroidism
Osteoporosis Temporal Arteritis

Graphical network of the top 20 diseases related to Polymyositis:



Diseases related to Polymyositis

Symptoms & Phenotypes for Polymyositis

Human phenotypes related to Polymyositis:

58 30 (show all 43)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 autoimmunity 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0002960
2 emg abnormality 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0003457
3 arthralgia 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0002829
4 cough 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0012735
5 elevated aldolase level 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0012544
6 abnormal muscle fiber morphology 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0004303
7 proximal muscle weakness 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0003701
8 hypotonia 30 Hallmark (90%) HP:0001252
9 elevated circulating creatine kinase concentration 30 Hallmark (90%) HP:0003236
10 constipation 58 30 Frequent (33%) Frequent (79-30%)
HP:0002019
11 respiratory insufficiency 58 30 Frequent (33%) Frequent (79-30%)
HP:0002093
12 arthritis 58 30 Frequent (33%) Frequent (79-30%)
HP:0001369
13 fatigue 58 30 Frequent (33%) Frequent (79-30%)
HP:0012378
14 fever 58 30 Frequent (33%) Frequent (79-30%)
HP:0001945
15 anorexia 58 30 Frequent (33%) Frequent (79-30%)
HP:0002039
16 myalgia 58 30 Frequent (33%) Frequent (79-30%)
HP:0003326
17 weight loss 58 30 Frequent (33%) Frequent (79-30%)
HP:0001824
18 exertional dyspnea 58 30 Frequent (33%) Frequent (79-30%)
HP:0002875
19 gait disturbance 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001288
20 dysphonia 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001618
21 hepatomegaly 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002240
22 gastroesophageal reflux 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002020
23 congestive heart failure 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001635
24 myocardial infarction 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001658
25 hypertrophic cardiomyopathy 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001639
26 venous thrombosis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0004936
27 pulmonary fibrosis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002206
28 dilated cardiomyopathy 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001644
29 reduced tendon reflexes 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001315
30 abnormal renal tubule morphology 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000091
31 abdominal pain 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002027
32 arrhythmia 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0011675
33 gastrointestinal hemorrhage 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002239
34 abnormal mitral valve morphology 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001633
35 pericarditis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001701
36 vasculitis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002633
37 breast carcinoma 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0003002
38 chondrocalcinosis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000934
39 abnormal atrioventricular conduction 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0005150
40 muscular hypotonia 58 Very frequent (99-80%)
41 elevated serum creatine kinase 58 Very frequent (99-80%)
42 abnormality of the voice 58 Occasional (29-5%)
43 interstitial pulmonary abnormality 58 Frequent (79-30%)

Drugs & Therapeutics for Polymyositis

Drugs for Polymyositis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 67)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
2
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
3
Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
4
Prednisolone Approved, Vet_approved Phase 3 50-24-8 4894 5755
5
Levoleucovorin Approved, Experimental, Investigational Phase 3 68538-85-2, 58-05-9, 73951-54-9 149436 6006
6
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 4112 126941
7
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5 1875
8
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 4159 6741
9
Tacrolimus Approved, Investigational Phase 2, Phase 3 104987-11-3 6473866 445643
10
Benzocaine Approved, Investigational Phase 2, Phase 3 1994-09-7, 94-09-7 2337
11
Tannic acid Approved Phase 2, Phase 3 1401-55-4 16129878 16129778
12
Alendronic acid Approved Phase 3 121268-17-5, 66376-36-1 2088
13
Ustekinumab Approved, Investigational Phase 3 815610-63-0
14
Abatacept Approved Phase 3 332348-12-6
15
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
16
Cholecalciferol Approved, Nutraceutical, Vet_approved Phase 3 67-97-0, 1406-16-2 5280795 10883523
17
Alfacalcidol Approved, Nutraceutical Phase 3 41294-56-8 5282181
18
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7 4897
19 Antibodies Phase 3
20 Immunoglobulins Phase 3
21 Antimetabolites Phase 3
22 Antineoplastic Agents, Hormonal Phase 3
23 glucocorticoids Phase 3
24 Folic Acid Antagonists Phase 3
25 Folate Phase 3
26
Methylprednisolone Acetate Phase 3 584547
27 Hormones Phase 3
28 Hormone Antagonists Phase 3
29 Vitamin B9 Phase 3
30 Vitamin B Complex Phase 3
31 Calcineurin Inhibitors Phase 2, Phase 3
32 gamma-Globulins Phase 3
33 Rho(D) Immune Globulin Phase 3
34 Immunoglobulins, Intravenous Phase 3
35 Interleukin 1 Receptor Antagonist Protein Phase 2, Phase 3
36 Micronutrients Phase 3
37 Calciferol Phase 3
38 Vitamins Phase 3
39 Trace Elements Phase 3
40 Hydroxycholecalciferols Phase 3
41 Immunosuppressive Agents Phase 3
42 Immunologic Factors Phase 3
43 Dermatologic Agents Phase 3
44 Antirheumatic Agents Phase 3
45 Immune Checkpoint Inhibitors Phase 3
46
Methimazole Approved Phase 2 60-56-0 1349907
47
Infliximab Approved Phase 2 170277-31-3
48
Rituximab Approved Phase 2 174722-31-7
49
Siponimod Approved, Investigational Phase 2 1230487-00-9 44599207
50 Antithyroid Agents Phase 2

Interventional clinical trials:

(show all 47)
# Name Status NCT ID Phase Drugs
1 A Prospective, Randomised, Assessor-blind, Multicenter Study of Efficacy and Safety of Combined Treatment of Methotrexate + Glucocorticoids Versus Glucocorticoids Alone in Patients With Polymyositis and Dermatomyositis. Completed NCT00651040 Phase 3 Prednisone;Methotrexate
2 An Open-label Clinical Trial of the Combination Treatment of Tacrolimus and Corticosteroid in Polymyositis/Dermatomyositis Patients With Interstitial Pneumonitis, With Comparison Against Corticosteroid-treated Historical Controls Completed NCT00504348 Phase 2, Phase 3 Tacrolimus
3 A Randomized, Double-blind, Controlled Clinical Study of GB-0998 for the Steroid-resistant Polymyositis and Dermatomyositis Completed NCT00335985 Phase 3 GB-0998;Placebo of GB-0998
4 Anakinra in Patients With Refractory Idiopathic Inflammatory Myopathies Completed NCT01165008 Phase 2, Phase 3 Anakinra
5 Prevention of Glucocorticoid-Induced Osteoporosis in Patients With Rheumatic Diseases. The STOP-Study: a Randomized Placebo Controlled Trial With Alendronate Versus Alfacalcidol. Completed NCT00138983 Phase 3 Alendronate versus alfacalcidol (1-alpha OH vitamin D)
6 A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Ustekinumab in Participants With Active Polymyositis and Dermatomyositis Who Have Not Adequately Responded to One or More Standard-of-care Treatments Terminated NCT03981744 Phase 3 Ustekinumab 6 mg/kg;Ustekinumab 90 mg;Placebo IV;Placebo SC
7 A Phase 3, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Abatacept SC With Standard Treatment Compared to Standard Treatment Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy (IIM) Terminated NCT02971683 Phase 3 Abatacept subcutaneous;Placebo
8 Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis Completed NCT02043548 Phase 2 tocilizumab;placebo
9 A Pilot Study of the Role of Methimazole in Patients With Polymyositis and Dermatomyositis Completed NCT00001421 Phase 2 methimazole
10 A Randomized, Double-Blind, Placebo-Controlled Trial of Infliximab in Patients With Dermatomyositis and Polymyositis Completed NCT00033891 Phase 2 Infliximab
11 A Phase 2 Randomized, Double-blind, Placebo-controlled, Crossover Multicenter Study to Evaluate the Safety and Efficacy of KZR-616 in the Treatment of Patients With Active Polymyositis or Dermatomyositis Completed NCT04033926 Phase 2 KZR-616;Placebo
12 Efficacy of an Individual Rehabilitation Program in Polymyositis and Dermatomyositis Completed NCT01415219 Phase 2
13 Abatacept Treatment in Polymyositis and Dermatomyositis Completed NCT01315938 Phase 2 Abatacept Active Treatment;Abatacept Delayed-Onset Treatment
14 Open Label Proof of Concept Study to Evaluate Efficacy and Safety of Adrenocorticotropic Hormone Gel in Refractory Dermatomyositis or Polymyositis Completed NCT01906372 Phase 2 Adrenocorticotropic Hormone Gel
15 The Efficacy of High-Dose Intravenous Immunoglobulin in Patients With Inflammatory Myopathies: A Three Month Randomized Trial With Option for Cross-Over Completed NCT00001261 Phase 2 Gamma Globulin
16 Rituximab Therapy in Refractory Adult and Juvenile Idiopathic Inflammatory Myopathy (IIM) Completed NCT00106184 Phase 2 Rituximab;Placebo
17 A Prospective, Open, Dose-escalation, Multi-center, Phase 1/2a Trial to Evaluate the Safety, Tolerability and to Explore the Efficacy of PN-101 in Patients With Refractory Polymyositis or Dermatomyositis Enrolling by invitation NCT04976140 Phase 1, Phase 2
18 An Open-label Extension to the Phase 2 Randomized, Double-blind, Placebo-controlled, Crossover Multicenter Study to Evaluate the Safety and Efficacy of KZR-616 in the Treatment of Patients With Active Polymyositis or Dermatomyositis Enrolling by invitation NCT04628936 Phase 2 KZR-616
19 A Multi-centre, Double-blind, Placebo Controlled, Proof of Concept Study to Evaluate the Efficacy and Tolerability of BAF312 in Patients With Polymyositis and Dermatomyositis Terminated NCT01148810 Phase 2 BAF312;Placebo
20 A Multi-centre Double-blind, Placebo Controlled, Proof of Concept Study to Evaluate the Efficacy and Tolerability of BAF312 in Patients With Polymyositis Terminated NCT01801917 Phase 2 Placebo;BAF312
21 A Phase 1 Randomized, Placebo-Controlled, Blinded, Multiple Ascending Dose Study to Evaluate VIB7734 in Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus, Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis Completed NCT03817424 Phase 1 VIB7734;Placebo
22 A Phase 1B, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate Safety of Multiple-Dose, Intravenously Administered MEDI-545, A Fully Human Anti Interferon-Alpha Monoclonal Antibody, In Adult Patients With Dermatomyositis or Polymyositis Completed NCT00533091 Phase 1
23 A Phase 1, Randomized, Blinded, Single-Dose, Dose Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of MEDI7734 in Type I Interferon-Mediated Autoimmune Diseases Completed NCT02780674 Phase 1
24 Effects of High-intensity Interval Training (HIIT) Compared to Low-intensity Exercise in Patients With Recent Onset Polymyositis and Dermatomyositis - a Randomized Controlled Trial Unknown status NCT03324152
25 Acthar Dermatomyositis and Polymyositis Treatment Unknown status NCT01637064 Acthar
26 Hand Function, Health Related Quality of Life and Activity Performance in Patients With Polymyositis or Dermatomyositis. Completed NCT00866125
27 Study of the Prevalence of Polymyositis and Dermatomyositis in Normandy Completed NCT02880527
28 Specified Drug Use-results Survey for Long-term Use of Prograf Capsules in Patient With Interstitial Pneumonia Associated With Polymyositis/Dermatomyositis Completed NCT02159651 tacrolimus
29 Outcome of Muscle Function and Disease Activity in Patients With Recent Onset Polymyositis and Dermatomyositis - a 1-year Follow-up Register Study Completed NCT01813617 Immunosuppressive Agents
30 Prevalence of Inflammatory Myopathies in Alsace Completed NCT02881450
31 Diagnostic Accuracy of Whole Body Magnetic Resonance Imaging in Inflammatory Myopathies Completed NCT01432613
32 Determining the Association Between Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity Completed NCT03941184
33 Genetic and Family Studies of Inherited Muscle Diseases Completed NCT00001331
34 Transcriptome Analysis Through a Dedicated Macro-array and TcLandscape Repertoire Analysis for Diagnosis of Myositis. Completed NCT00213629
35 Studies of the Natural History and Pathogenesis of Autoimmune/Connective Tissue Diseases Completed NCT00341679
36 Exploration of the Diagnostic Capabilities of Ultrasound of the Oropharynx and Larynx Completed NCT00001167
37 Predictor of Clinical Response to Acthar in Myositis: Phase II of Acthar Clinical Trial Completed NCT03414086
38 Environmental Risk Factors for the Anti-Synthetase Syndrome Recruiting NCT01276470
39 Phase 1 Study of Mesenchymal Stromal Cells, Umbilical Cord Lining Stem Cells (ULSC), in Patients With Polymyositis (PM) and Dermatomyositis (DM) Recruiting NCT04723303 Early Phase 1 Umbilical Cord Lining Stem Cells
40 Studies on the Natural History and Pathogenesis of Polymyositis, Dermatomyositis, and Related Diseases Recruiting NCT00001265
41 Rheumatology Patient Registry and Biorepository Recruiting NCT04402086
42 Studies in the Natural History and Pathogenesis of Childhood-Onset and Adult-Onset Idiopathic Inflammatory Myopathies Recruiting NCT00017914
43 Identification of Disease Susceptibility Genes Associated With Development and Clinical Characteristics of Primary Inflammatory Muscle Diseases, PM, DM and IBM. Recruiting NCT01171573
44 High-intensity Strength Training in Patients With Idiopathic Inflammatory Myopathies: Changes in Quality of Life, Muscle Strength, Function and Myocellular Parameters Active, not recruiting NCT04486261
45 Environmental Risk Factors for the Development of Myositis in Military Personnel Active, not recruiting NCT01734369
46 Correlation of "Myositis Functional Index-3 (Fi-3)" With Muscle Function Assessed by Isokinetic Dynamometry and Effects of Repetitive Task Training in Patients With Inflammatory Myopaties Not yet recruiting NCT05027152
47 Lipid-lowering Agents in Patients With Dermatomyositis and Polymyositis Terminated NCT03092154 Lipid-lowering agents (Artovastatin)

Search NIH Clinical Center for Polymyositis

Genetic Tests for Polymyositis

Anatomical Context for Polymyositis

Organs/tissues related to Polymyositis:

MalaCards : Skeletal Muscle, Heart, Bone, Breast, Lung, T Cells, Bone Marrow

Publications for Polymyositis

Articles related to Polymyositis:

(show top 50) (show all 6129)
# Title Authors PMID Year
1
Distinctive patterns of microRNA expression in primary muscular disorders. 62 46
17942673 2007
2
Expression of TLR2, TLR4, and TLR9 in dermatomyositis and polymyositis. 53 62
19953283 2010
3
Beware of 'normal' creatine kinase levels in HIV-associated polymyositis. 53 62
20459937 2010
4
Dysferlin deficiency treated like refractory polymyositis. 53 62
19730931 2010
5
A dual role for HSP90 and HSP70 in the inflammatory myopathies: from muscle fiber protection to active invasion by macrophages. 53 62
19758187 2009
6
Th1 and Th17 balance in inflammatory myopathies: interaction with dendritic cells and possible link with response to high-dose immunoglobulins. 53 62
19303320 2009
7
[An autopsied case of thoracic esophageal cancer with polymyositis]. 53 62
19498309 2009
8
[A case of chronic graft-versus-host disease presenting with polymyositis]. 53 62
19404011 2009
9
Nonspecific interstitial pneumonia associated with collagen vascular disease: analysis of CT features to distinguish the various types. 53 62
19443969 2009
10
Dysferlin deficiency enhances monocyte phagocytosis: a model for the inflammatory onset of limb-girdle muscular dystrophy 2B. 53 62
18276788 2008
11
Acute myopathy in a patient with oesophageal stricture. 53 62
17965038 2007
12
Rituximab for refractory polymyositis: an open-label prospective study. 53 62
17722224 2007
13
Inducible overexpression of wild-type prion protein in the muscles leads to a primary myopathy in transgenic mice. 53 62
17420473 2007
14
Immunolocalization of interleukin-1 receptors in the sarcolemma and nuclei of skeletal muscle in patients with idiopathic inflammatory myopathies. 53 62
17265504 2007
15
Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic review. 53 62
17207162 2007
16
Signs of inflammation in both symptomatic and asymptomatic muscles from patients with polymyositis and dermatomyositis. 53 62
16831829 2006
17
Expression of CCR7 and its ligands CCL19/CCL21 in muscles of polymyositis. 53 62
16887149 2006
18
Muscle inflammation, autoimmune Addison's disease and sarcoidosis in a patient with dysferlin deficiency. 53 62
16483775 2006
19
Difference in adhesion molecule expression (ICAM-1 and VCAM-1) in juvenile and adult dermatomyositis, polymyositis and inclusion body myositis. 53 62
16431335 2006
20
Autoantibodies against the replication protein A complex in systemic lupus erythematosus and other autoimmune diseases. 53 62
16846524 2006
21
Chemokine receptor CCR7 is expressed in muscle fibers in juvenile dermatomyositis. 53 62
15950936 2005
22
Changes of single fiber electromyography in patients with inflammatory myopathies. 53 62
15844301 2005
23
The electromyographic features of acute rhabdomyolysis. 53 62
19078759 2005
24
[A study of vascular factor in the pathogenesis of polymyositis]. 53 62
15840223 2005
25
The prion protein in human neuromuscular diseases. 53 62
15476279 2004
26
Immunolocalization of protectin (CD59) and macrophages in polymyositis and dermatomyositis. 53 62
15020079 2004
27
Anticyclic citrullinated peptide antibodies in patients with mixed connective tissue disease. 53 62
17143695 2004
28
Muscle inflammation and MHC class I up-regulation in muscular dystrophy with lack of dysferlin: an immunopathological study. 53 62
14512171 2003
29
Expression of calcium-binding proteins MRP8 and MRP14 in inflammatory muscle diseases. 53 62
12937135 2003
30
S-protein is expressed in necrotic fibers in Duchenne muscular dystrophy and polymyositis. 53 62
12707977 2003
31
Interleukin-17 increases the effects of IL-1 beta on muscle cells: arguments for the role of T cells in the pathogenesis of myositis. 53 62
12667656 2003
32
Relationship between utrophin and regenerating muscle fibers in duchenne muscular dystrophy. 53 62
12619170 2003
33
Expression of the costimulatory molecule BB-1 and its receptors in patients with scleroderma-polymyositis overlap syndrome. 53 62
12409186 2002
34
Clinical significance of serum surfactant protein D (SP-D) in patients with polymyositis/dermatomyositis: correlation with interstitial lung disease. 53 62
12421999 2002
35
Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and immature dendritic cells. 53 62
12235211 2002
36
Overview of neuromuscular disorders affecting respiratory function. 53 62
16088611 2002
37
Recurrent acute myositis after allogeneic bone marrow transplantation for myelodysplasia. 53 62
12186701 2002
38
Interleukin-1alpha expression in capillaries and major histocompatibility complex class I expression in type II muscle fibers from polymyositis and dermatomyositis patients: important pathogenic features independent of inflammatory cell clusters in muscle tissue. 53 62
11953983 2002
39
Women with pregnancy-related polymyositis and high serum CK levels in the newborn. 53 62
11839858 2002
40
Serum levels of interleukin 15 in patients with rheumatic diseases. 53 62
11708407 2001
41
Polymyositis evolving after rhabdomyolysis associated with HMG-CoA reductase inhibitors: a report of two cases. 53 62
17039165 2001
42
Increased expression of the normal cellular isoform of prion protein in inclusion-body myositis, inflammatory myopathies and denervation atrophy. 53 62
11303793 2001
43
Cardiac troponin and beta-type myosin heavy chain concentrations in patients with polymyositis or dermatomyositis. 53 62
11282091 2001
44
Titin and ryanodine receptor autoantibodies in dogs with thymoma and late-onset myasthenia gravis. 53 62
11182151 2001
45
Increased interleukin-17 production in patients with systemic sclerosis. 53 62
11083268 2000
46
Increased serum levels of soluble vascular cell adhesion molecule-1 and soluble E-selectin in patients with polymyositis/dermatomyositis. 53 62
10951151 2000
47
Expression of human IAP-like protein in skeletal muscle: a possible explanation for the rare incidence of muscle fiber apoptosis in T-cell mediated inflammatory myopathies. 53 62
10814776 2000
48
Increased CD40 expression on muscle cells of polymyositis and dermatomyositis: role of CD40-CD40 ligand interaction in IL-6, IL-8, IL-15, and monocyte chemoattractant protein-1 production. 53 62
10843719 2000
49
AlphaB-crystallin immunolocalization yields new insights into inclusion body myositis. 53 62
10720271 2000
50
Increased expression of beta-chemokines in muscle of patients with inflammatory myopathies. 53 62
10749105 2000

Variations for Polymyositis

Expression for Polymyositis

Search GEO for disease gene expression data for Polymyositis.

Pathways for Polymyositis

GO Terms for Polymyositis

Cellular components related to Polymyositis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.9 MIR99B MIR501 MIR30A MIR222 MIR221 MIR210
2 RISC complex GO:0016442 9.85 MIR127 MIR130A MIR132 MIR146B MIR154 MIR155
3 extracellular vesicle GO:1903561 9.5 MIR34A MIR30A MIR222 MIR221 MIR214 MIR21

Biological processes related to Polymyositis according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.95 MIR99B MIR34A MIR214 MIR21 MIR155 MIR132
2 positive regulation of protein kinase B signaling GO:0051897 9.89 MIR222 MIR221 MIR21 MIR132
3 negative regulation of angiogenesis GO:0016525 9.87 MIR21 MIR214 MIR222 MIR34A
4 miRNA-mediated gene silencing GO:0035195 9.84 MIR127 MIR130A MIR132 MIR146B MIR154 MIR155
5 positive regulation of epithelial to mesenchymal transition GO:0010718 9.79 MIR222 MIR221 MIR21
6 positive regulation of G1/S transition of mitotic cell cycle GO:1900087 9.79 MIR222 MIR221 MIR214
7 positive regulation of blood vessel endothelial cell migration GO:0043536 9.78 MIR30A MIR221 MIR210
8 negative regulation of vascular associated smooth muscle cell proliferation GO:1904706 9.76 MIR362 MIR34A MIR214
9 positive regulation of vascular endothelial cell proliferation GO:1905564 9.71 MIR21 MIR132 MIR130A
10 positive regulation of angiogenesis GO:0045766 9.7 MIR99B MIR30A MIR210 MIR21 MIR199B MIR132
11 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.67 MIR362 MIR34A MIR214 MIR21
12 positive regulation of vascular associated smooth muscle cell proliferation GO:1904707 9.65 MIR222 MIR221 MIR214 MIR21 MIR130A
13 positive regulation of axon regeneration GO:0048680 9.64 MIR222 MIR221
14 negative regulation of cell adhesion molecule production GO:0060354 9.63 MIR222 MIR221
15 negative regulation by host of viral genome replication GO:0044828 9.63 MIR222 MIR221
16 miRNA-mediated gene silencing by mRNA destabilization GO:0035279 9.63 MIR214 MIR210 MIR130A
17 positive regulation of connective tissue replacement GO:1905205 9.62 MIR34A MIR214
18 positive regulation of endothelial cell differentiation GO:0045603 9.61 MIR99B MIR21 MIR199B
19 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.6 MIR210 MIR21
20 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.58 MIR222 MIR221
21 negative regulation of BMP secretion GO:2001285 9.56 MIR214 MIR210
22 negative regulation of hematopoietic stem cell proliferation GO:1902034 9.55 MIR222 MIR221
23 positive regulation of vascular associated smooth muscle cell dedifferentiation GO:1905176 9.52 MIR221 MIR214
24 negative regulation of TRAIL-activated apoptotic signaling pathway GO:1903122 9.51 MIR222 MIR221
25 negative regulation of interleukin-21 production GO:0032705 9.5 MIR222 MIR221 MIR21
26 positive regulation of Schwann cell migration GO:1900149 9.49 MIR222 MIR221
27 miRNA-mediated gene silencing by inhibition of translation GO:0035278 9.43 MIR132 MIR21 MIR210 MIR221 MIR222 MIR379
28 positive regulation of Schwann cell proliferation involved in axon regeneration GO:1905046 9.4 MIR221 MIR222

Molecular functions related to Polymyositis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA 3'-UTR binding GO:0003730 9.7 MIR99B MIR501 MIR379 MIR34A MIR30A MIR214
2 mRNA base-pairing translational repressor activity GO:1903231 9.58 MIR99B MIR501 MIR379 MIR362 MIR34A MIR30A

Sources for Polymyositis

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 24-Oct-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....